Table 1 Baseline characteristics
Variables | AFP | P value | DCP | P value | |||
|---|---|---|---|---|---|---|---|
All patients | AFP responder | AFP non-responder | DCP responder | DCP non-responder | |||
(n = 115) | (n = 91, 79.1%) | (n = 24, 20.9%) | (n = 77, 66.9%) | (n = 38, 33.1%) | |||
Age, years | 59 (37 - 78) | 59 (37 - 78) | 59 (39 - 75) | 0.783 | 59 (37 - 78) | 59.9 (40 - 77) | 0.661 |
Male | 81 (70.4) | 63 (69.2) | 18 (75.0) | 0.802 | 53 (68.8) | 28 (73.7) | 0.668 |
Etiology | |||||||
HBV/ HCV/ Others | 80 (69.5)/ 18 (15.7)/ 17 (14.8) | 63 (69.2)/ 15 (16.5) /13 (14.3) | 17 (70.8)/ 3 (12.5)/ 4 (16.7) | 0.883 | 53 (68.8)/ 13 (16.9)/ 11 (14.3) | 27 (71.0)/ 5 (13.2)/ 6 (15.8) | 0.908 |
Child-Pugh, A vs. B | 108 (93.9)/ 7 (6.1) | 89 (97.8)/ 2 (2.2) | 19 (79.2)/ 5 (20.8) | 0.004 | 74 (96.1) / 3 (3.9) | 34 (89.5)/ 4(10.5) | 0.217 |
Liver cirrhosis | 72 (62.6)/ 43 (37.4) | 56 (61.5)/ 35 (38.5) | 16 (66.7)/ 8(33.3) | 0.813 | 46 (59.7) / 31 (40.3) | 26 (68.4)/ 12(31.6) | 0.417 |
Biochemical Variables | |||||||
Platelet, 103/uL | 127 (38 - 414) | 134 (38 - 332) | 108 (64 - 414) | 0.585 | 123 (38 - 332) | 133.5 (60-414) | 0.467 |
ALT, IU/L | 38 (12 - 315) | 39 (12 - 315) | 38 (18 - 116) | 0.088 | 39 (12 - 257) | 37 (18 - 315) | 0.561 |
Bilirubin, mg/dL | 0.7 (0.2 - 13.4) | 0.7 (0.2 - 3.0) | 0.6 (0.3 - 13.4) | 0.405 | 0.7 (0.2 - 3.0) | 0.6 (0.2-13.4) | 0.462 |
AFP, ng/mL | 296.7 (24.23 - 83000) | 320.95 (24.23 - 50000) | 142.96 (26 - 83000) | 0.496 | 320.95 (24.23 - 83000) | 280.08 (25.22 - 50000) | 0.774 |
DCP, mAU/mL | 231 (20 - 2000) | 231 (20 - 2000) | 228.5 (23 - 2000) | 0.304 | 276 (20 - 2000) | 62.5 (20 - 2000) | 0.464 |
Number of tumora | |||||||
1/ 2/ 3/ >4 | 60 (52.2)/ 18 (15.7)/ 9 (7.8)/ 28 (24.3) | 13 (54.2)/ 5 (20.8)/ 2 (8.3)/ 4 (16.7) | 47 (51,6)/ 13 (14.3)/ 7 (7.7)/ 24 (26.4) | 0.732 | 35(45.4)/ 13 (16.9)/ 6 (7.8)/ 23 (29.9) | 25 (65,8)/ 5 (13.2)/ 3(8.0)/ 5(13.2) | 0.160 |
Size of tumor, mmb | 47 (10 - 160) | 47 (10 - 160) | 45.5 (10 - 151) | 0.531 | 49 (10 - 160) | 36 (10 - 160) | 0.473 |
BCLC stage | |||||||
A/ B/ C | 62 (53.9)/ 49 (42.6)/ 4 (3.5) | 47 (51.6)/ 40 (44.0)/ 4 (4.4) | 15 (62.5)/ 9 (37.5)/ 0 (0.0) | 0.484 | 40 (51.9)/ 36 (46.8)/ 1 (1.3) | 22 (57.9)/ 13 (34.2)/ 3 (7.9) | 0.117 |
TNM stage of LCSGJ | |||||||
I/ II/ III/ IVa | 21 (18.3)/ 40 (34.8)/ | 19 (20.9)/ 29 (31.9)/ | 2 (8.3)/ 11 (45.8)/ | 0.412 | 9 (11.7)/ 31 (40.3)/ | 12 (31.6)/ 9 (23.7)/ | 0.027 |
42 (36.5)/ 12 (10.4) | 34 (37.4)/ 9 (9.9) | 8 (33.3)/ 3 (1.5) | 27 (35.1)/ 10 (13.0) | 15 (39.5)/ 2 (5.3) | |||